Urologas Utenoje - Company finances
|
EUR
|
2022
From: 2022-10-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|
|
Financial data
|
||||
| Sales revenue | - | 729 | 4,721 | 8,758 |
| Profit before tax | -319 | -1,956 | 1,920 | 4,568 |
| Net profit | -319 | -1,956 | 1,891 | 4,368 |
| Equity | 81 | 125 | 2,366 | 4,592 |
| Liabilities | 52 | 167 | 84 | 267 |
| Non-current assets | 0 | 0 | 0 | 2,363 |
| Current assets | 133 | 292 | 2,450 | 2,496 |
| Total assets | 133 | 292 | 2,450 | 4,859 |
|
Taxes paid
|
||||
| STI taxes | - | 397 | 322 | 293 |
|
Financial indicators
|
||||
| Revenue change y/y | - | - | +547.6% | +85.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -239.8% | -669.9% | 77.2% | 89.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -393.8% | -1564.8% | 79.9% | 95.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | -268.3% | 40.1% | 49.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | -268.3% | 40.7% | 52.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.6 | 1.3 | 0.0 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Urologas Utenoje - Social security debts
The company had no debts to Sodra
Urologas Utenoje - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Urologas Utenoje, MB (code 306150700) is a Small partnership operating in medical specialists activities. In 2025, the company increased revenue to €8.8K, up 85.5% year on year and more than elevenfold compared with 2023. Profitability also strengthened markedly: net profit reached €4.4K in 2025, after a net loss of €2.0K in 2023 and profit of €1.9K in 2024. The 2025 profit margin was 49.9%, showing that nearly half of turnover translated into bottom-line profit.
The balance sheet remained very conservative. At the end of 2025, total assets were €4.9K, supported by equity of €4.6K and liabilities of €267. Equity accounted for 94.5% of assets, while debt-to-equity stood at 0.06. Assets were split almost evenly between €2.5K in short-term assets and €2.4K in long-term assets. Efficiency indicators were strong for the latest year, with asset turnover at 1.80x, ROE at 95.1% and ROA at 89.9%.
The balance sheet remained very conservative. At the end of 2025, total assets were €4.9K, supported by equity of €4.6K and liabilities of €267. Equity accounted for 94.5% of assets, while debt-to-equity stood at 0.06. Assets were split almost evenly between €2.5K in short-term assets and €2.4K in long-term assets. Efficiency indicators were strong for the latest year, with asset turnover at 1.80x, ROE at 95.1% and ROA at 89.9%.